Abstract
OBJECTIVE
To investigate the effectiveness of 0.05% cyclosporin A therapy in children with severe vernal keratoconjunctivitis
METHODS
Between 2010 and 2012, 19 patients with a diagnosis of vernal keratoconjunctivitis were involved into the study. The diagnosis of vernal conjunctivitis was made according to the presence of typical clinical symptoms. The symptoms and signs determined in the patients were seperately scored. For each patient, topical cyclosporine treatment was initiated, and at the 3. and 6. months of the therapy, scoring of the symptoms and signs were performed again.
RESULTS
The mean age of the participating patients (12 male, 7 female) was 10.1 ± 1.7. The scores of the symptoms showed significant improvement during the controls performed at the 3. and 6. months of the treatment. Despite the scores were not significantly improved at the 3. month of the treatment; significant improvements were observed during the controls at the 6.month of the treatment. No adverse effects which causes the end of treatment were observed.
CONCLUSION
Topical 0.05% cyclosporine A treatment was proved to cause significant improvement in clinical signs and symptoms in severe patients with active vernal keratoconjunctivitis. The need for steroids was found to be significantly reduced in these cases. The drug is well tolerated locally.
Keywords: vernal keratoconjunctivitis, cyclosporine A, prognosis
